Heart drug safety check completed in small indian study
NCT ID NCT06086353
Summary
This study aimed to monitor the safety of the drug Tafamidis (VyndaMx®) in Indian patients with a specific heart condition called ATTR-CM, where a protein clumps in the heart. Six adult patients who were already prescribed the drug participated, and researchers tracked any side effects they experienced over six months. The goal was to gather real-world safety information, with follow-ups conducted either in clinic or by phone.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRANSTHYRETIN AMYLOID CARDIOMYOPATHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AIG Hospital
Hyderabad, 500032, India
-
Max Super Speciality Hospital
New Delhi, 110017, India
-
Sri Jayadeva Institute of Cardiovascular Sciences and Research
Bangalore, Karnataka, 560069, India
Conditions
Explore the condition pages connected to this study.